MedTrace Logo

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

NCT00165698 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2014-07-22

Study results available
· View outcomes & findings →

Summary

To determine the effect and safety of menatetrenone on treatment of postmenopausal osteoporosis comparing with alfacalcidol.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

menatetranone

15 mg three times a day orally for 12 months

DRUG

alfacalcidol

0.25 μg twice a day orally for 12 months

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hong Di · Eisai China Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-01-31
Completion
2007-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165698 on ClinicalTrials.gov